Zenas Biopharma (ZBIO) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for Zenas Biopharma (ZBIO).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||
Total Revenue | - | - | - | - | 10M (+100.00%) | 5.00M | - | - | - | - | 50M | - | - |
Operating Expenses | |||||||||||||
Research And Development | 60M (+8.47%) | 56M (+61.98%) | 34M (-20.06%) | 43M (+23.22%) | 35M (-28.97%) | 49M (+46.61%) | 34M (-0.83%) | 34M (+49.27%) | 23M (-55.31%) | 51M (+442.03%) | 9.35M | - | - |
Selling General And Administrative | 17M (+8.47%) | 16M (+18.29%) | 13M (+8.57%) | 12M (-2.25%) | 12M (+8.28%) | 11M (+53.96%) | 7.45M (+26.27%) | 5.90M (+19.68%) | 4.93M (-59.22%) | 12M (+140.84%) | 5.02M | - | - |
Operating Expenses | 77M (-67.50%) | 238M (+352.61%) | 53M (-4.68%) | 55M (+16.54%) | 47M (-21.92%) | 61M (+47.93%) | 41M (+3.22%) | 40M (+43.94%) | 28M (-62.10%) | 73M (+406.05%) | 14M | - | - |
Depreciation And Amortization | 10K (-66.67%) | 30K | - | - | 20K (-80.00%) | 100K | - | - | 30K (-72.73%) | 110K | - | - | - |
Operating Income | |||||||||||||
Operating Income | -77.35M (-67.50%) | -237.98M (+352.61%) | -52.58M (-4.68%) | -55.16M (+47.76%) | -37.33M (-32.88%) | -55.62M (+35.72%) | -40.98M (+3.22%) | -39.70M (+43.94%) | -27.58M (-62.10%) | -72.77M | 36M | - | - |
Ebit | -77.35M (-67.50%) | -237.98M (+352.61%) | -52.58M (-4.68%) | -55.16M (+47.76%) | -37.33M (-32.88%) | -55.62M (+35.72%) | -40.98M (+3.22%) | -39.70M (+43.94%) | -27.58M (+11.98%) | -24.63M | 36M | -29.05M (+52.09%) | -19.10M |
EBITDA | -77.34M (-68.04%) | -241.99M (+369.88%) | -51.50M (-1.34%) | -52.20M (+39.91%) | -37.31M (-37.42%) | -59.62M (+54.42%) | -38.61M (+1.66%) | -37.98M (+37.91%) | -27.54M (+12.41%) | -24.50M | 36M | -29.05M (+52.09%) | -19.10M |
Other Income / Expenses | |||||||||||||
Interest Income | 3.02M (-65.53%) | 8.76M | - | - | 3.39M (-57.47%) | 7.97M | - | - | - | - | - | - | - |
Interest Expense | 370K (-94.95%) | 7.33M | - | - | - | - | - | - | - | - | - | - | - |
Net Interest Income | 3.02M (-65.53%) | 8.76M | - | - | 3.39M (-57.47%) | 7.97M | - | - | - | - | - | - | - |
Other Non Operating Income | -20.00K | 420K (-61.11%) | 1.08M (-63.51%) | 2.96M (+1750.00%) | 160K (-20.00%) | 200K (-91.60%) | 2.38M (+26.60%) | 1.88M (+300.00%) | 470K (-24.19%) | 620K | -20.00K | - | - |
Net Income | |||||||||||||
Income Before Tax | -80.99M (-66.30%) | -240.34M (+366.68%) | -51.50M (-1.34%) | -52.20M (+54.53%) | -33.78M (-35.26%) | -52.18M (+35.15%) | -38.61M (+1.66%) | -37.98M (+36.62%) | -27.80M (-24.50%) | -36.82M | - | - | - |
Income Tax Expense | - | 110K | - | 20K | -200.00K | 430K | - | - | - | 300K | - | - | - |
Net Income From Continuing Operations | -80.99M (-66.32%) | -240.44M (+366.87%) | -51.50M (-1.38%) | -52.22M (+55.56%) | -33.57M (-36.18%) | -52.60M (+36.23%) | -38.61M (+1.66%) | -37.98M (+36.62%) | -27.80M (+13.05%) | -24.59M | 36M | -29.05M (+52.09%) | -19.10M |
Net Income | -80.99M (-66.32%) | -240.44M (+366.87%) | -51.50M (-1.38%) | -52.22M (+55.56%) | -33.57M (-36.18%) | -52.60M (+36.23%) | -38.61M (+1.66%) | -37.98M (+36.62%) | -27.80M (+13.05%) | -24.59M | 36M | -29.05M (+52.09%) | -19.10M |
Comprehensive Income Net Of Tax | -81.30M (-78.49%) | -377.99M (+634.39%) | -51.47M (-1.89%) | -52.46M (+55.99%) | -33.63M (-78.56%) | -156.83M (+305.66%) | -38.66M (+1.87%) | -37.95M (+36.71%) | -27.76M (-25.07%) | -37.05M | 36M | - | - |